{"doi":"10.1101/2020.07.27.223206","title":"ImmunoPET-informed sequence for focused ultrasound-targeted mCD47 blockade controls glioma","abstract":"Abstract Phagocytic immunotherapies such as CD47 blockade have emerged as promising strategies for glioblastoma (GB) therapy, but the blood brain/tumor barriers (BBB/BTB) pose a persistent challenge for mCD47 delivery that can be overcome by focused ultrasound (FUS)-mediated BBB/BTB disruption. We here leverage immuno-PET imaging to determine how timing of [ 89 Zr]-mCD47 injection relative to FUS impacts antibody penetrance into orthotopic murine gliomas. We then design and implement a rational paradigm for combining FUS and mCD47 for glioma therapy. We demonstrate that timing of antibody injection relative to FUS BBB/BTB disruption is a critical determinant of mCD47 access, with post-FUS injection conferring superlative antibody delivery to gliomas. We also show that mCD47 delivery across the BBB/BTB with repeat sessions of FUS can significantly constrain tumor outgrowth and extend survival in glioma-bearing mice. This study generates provocative insights for ongoing pre-clinical and clinical evaluations of FUS-mediated antibody delivery to brain tumors. Moreover, our results confirm that mCD47 delivery with FUS is a promising therapeutic strategy for GB therapy.","journal":"bioRxiv (Cold Spring Harbor Laboratory)","year":2020,"id":123912,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":3,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9494,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":394487,"name":"Soumen Paul","orcid":"0000-0001-6706-6205","position":1,"is_corresponding":false},{"id":568117,"name":"Katelyenn S. McCauley","orcid":null,"position":2,"is_corresponding":false},{"id":567547,"name":"Victoria R. Breza","orcid":"0000-0003-2294-7222","position":3,"is_corresponding":false},{"id":343898,"name":"Stuart S. Berr","orcid":"0000-0002-3110-8140","position":4,"is_corresponding":false},{"id":323798,"name":"G. Wilson Miller","orcid":"0000-0002-4833-8321","position":5,"is_corresponding":false},{"id":567548,"name":"Kiel D. Neumann","orcid":"0000-0001-9093-3522","position":6,"is_corresponding":false},{"id":232551,"name":"Richard J. Price","orcid":"0000-0002-0237-2102","position":7,"is_corresponding":false},{"id":318539,"name":"Natasha Sheybani","orcid":"0000-0002-1137-058X","position":0,"is_corresponding":true}],"reference_count":51,"raw_metadata":null,"created_at":"2026-07-18T23:15:03.403566Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}